Thera-SAbDab: the Therapeutic Structural Antibody Database

The Therapeutic Structural Antibody Database (Thera-SAbDab; http://opig.stats.ox.ac.uk/webapps/therasabdab) tracks all antibody- and nanobody-related therapeutics recognised by the World Health Organisation (WHO), and identifies any corresponding structures in the Structural Antibody Database (SAbDab) with near-exact or exact variable domain sequence matches. Thera-SAbDab is synchronised with SAbDab to update weekly, reflecting new Protein Data Bank entries and the availability of new sequence data published by the WHO. Each therapeutic summary page lists structural coverage (with links to the appropriate SAbDab entries), alignments showing where any near-matches deviate in sequence, and accompanying metadata, such as intended target and investigated conditions. Thera-SAbDab can be queried by therapeutic name, by a combination of metadata, or by variable domain sequence - returning all therapeutics that are within a specified sequence identity over a specified region of the query. The sequences of all therapeutics listed in Thera-SAbDab (461 unique molecules, as of 5th August 2019) are downloadable as a single file with accompanying metadata.

[1]  C. Deane,et al.  Antibody–antigen complex modelling in the era of immunoglobulin repertoire sequencing , 2019, Molecular Systems Design & Engineering.

[2]  C. Dumontet,et al.  Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.

[3]  A Mantalaris,et al.  The Increasingly Human and Profitable Monoclonal Antibody Market. , 2019, Trends in biotechnology.

[4]  Muhammed Tilahun Muhammed,et al.  Homology modeling in drug discovery: Overview, current applications, and future perspectives , 2018, Chemical biology & drug design.

[5]  Janice M Reichert,et al.  Antibodies to watch in 2019 , 2018, mAbs.

[6]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[7]  Jiye Shi,et al.  Five computational developability guidelines for therapeutic antibody profiling , 2019, Proceedings of the National Academy of Sciences.

[8]  Maja Kenig,et al.  PEGylation of antibody fragments for half-life extension. , 2012, Methods in molecular biology.

[9]  D. Neri,et al.  Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends , 2011, Clinical Cancer Research.

[10]  A. Lesk,et al.  Standard conformations for the canonical structures of immunoglobulins. , 1997, Journal of molecular biology.

[11]  Sebastian Kelm,et al.  SAbPred: a structure-based antibody prediction server , 2016, Nucleic Acids Res..

[12]  Charlotte M. Deane,et al.  ANARCI: antigen receptor numbering and receptor classification , 2015, Bioinform..

[13]  R. Vandenbroucke,et al.  Nanobodies as therapeutics: big opportunities for small antibodies. , 2016, Drug discovery today.

[14]  Bojana Popovic,et al.  Experimentally guided computational antibody affinity maturation with de novo docking, modelling and rational design , 2019, PLoS Comput. Biol..

[15]  Jiye Shi,et al.  SAbDab: the structural antibody database , 2013, Nucleic Acids Res..

[16]  Jiye Shi,et al.  ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimation , 2016, mAbs.

[17]  D. Clawson,et al.  Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease , 2019, mAbs.

[18]  R. V. van Montfort,et al.  Structure-based drug design: aiming for a perfect fit , 2017, Essays in biochemistry.

[19]  Janice M Reichert,et al.  Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.